The relationship of the BRAFV600E mutation and the established prognostic factors in papillary thyroid carcinomas

Endocrine Pathology

Volumn 23, Issue 3, 2012, Pages 135-140

  Kurt, Bülent ^a   YalçIn, Serap ^b   Alagöz, Engin ^a   KarslIoǧlu, Yildirim ^a   Yigit, Nuri ^a   Günal, Armaǧan ^a   Deveci, M Salih ^a  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

^b AHI EVRAN UNIVERSITY   (Turkey)

Author keywords

BRAFV600E; Diagnosis; Papillary thyroid carcinoma; Prognosis

Indexed keywords

B RAF KINASE;

ADULT; AGED; ARTICLE; BRAF V600E GENE; CANCER INVASION; CANCER STAGING; CLINICAL ARTICLE; COHORT ANALYSIS; DISTANT METASTASIS; ETHNIC GROUP; EXTRATHYROIDAL EXTENSION; FEMALE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MALE; ONCOGENE; PRIORITY JOURNAL; PROGNOSIS; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; THYROID CARCINOMA; THYROID GLAND; TURKISH;

ADOLESCENT; ADULT; AGED; CARCINOMA; DNA, NEOPLASM; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; RETROSPECTIVE STUDIES; THYROID NEOPLASMS; TURKEY;

EID: 84865063786     PISSN: 10463976     EISSN: 15590097     Source Type: Journal    
DOI: 10.1007/s12022-012-9218-7     Document Type: Article

References (22)

1. Jameson JL, Weetman AP: Disorders of the thyroid gland. Harrison's Principles of Internal Medicine, eds: Kasper DL, Fauci AS, Longo DL, Braunwald E, Hauser SL, Jameson JL. The McGraw Hill Companies, New York pp: 2014, 2005.
2. R Leboeuf JE Baumgartner M Benezra R Malaguarnera D Solit CA Pratilas N Rosen JA Knauf JA Fagin 2008 BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines J Clin Endocrinol Metab. 93 2194 2201 18381570 10.1210/jc.2007-2825 1:CAS:528:DC%2BD1cXntFamt7w%3D (Pubitemid 351831535)
3. T Kondo T Nakazawa S Murata, et al. 2007 Enhanced B-Raf protein expression is independent of V600E mutant status in thyroid carcinomas Hum Pathol. 38 12 1810 1818 17714762 10.1016/j.humpath.2007.04.014 1:CAS:528:DC%2BD2sXhtlOls7zF (Pubitemid 350179928)
4. A Chakraborty A Narkar R Mukhopadhyaya, et al. 2012 BRAF (V600E) mutation in papillary thyroid carcinoma: significant association with node metastases and extra thyroidal Invasion Endocr Pathol. 22 132 136
5. A Martur W Moses R Rahbari, et al. 2011 Higher rate of BRAF mutation in papillary thyroid cancer over time Cancer. 117 4390 4395 10.1002/cncr.26072
6. Y Ito H Yoshida R Maruo, et al. 2009 BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients Endocr J. 56 1 89 97 18840924 10.1507/endocrj.K08E-208 1:CAS:528:DC%2BD1MXlvVWgtrg%3D
7. YS Jo S Huang YJ Kim, et al. 2009 Diagnostic value of pyrosequencing for the BRAF V600E mutation in ultrasound-guided fine-needle aspiration biopsy samples of thyroid incidentalomas Clin Endocrinol (Oxf) 70 139 144 10.1111/j.1365-2265.2008.03293.x 1:CAS:528:DC%2BD1MXit1GrsLk%3D
8. P Salerno VD Falco A Tamburino, et al. 2009 Cytocytatic activity os ATP-competetive kinase inhibitors in BRAF mutant thyroid carcinoma cells J Clin Endocrinol Metab. 95 450 455 19880792 10.1210/jc.2009-0373
9. TY Kim WB Kim JY Song, et al. 2009 The BRAF mutation is not associated with prognostic factors in Korean patients with conventional papillary microcarcinomas Clin Endocrinol Oxf. 63 588 593 10.1111/j.1365-2265.2005.02389.x (Pubitemid 41626756)
10. X Mingzhao 2011 Prognostic utulity of BRAF mutation in papillary thyroid cancer Mol Cell Endocrinol 321 86 93
11. CJ O'neill M Bullock A Chou, et al. 2010 BRAF V600E mutation is associated with an increased risk of nodal recurrence requiring reoperative surgery in patients with papillary thyroid cancer Surgery. 148 1139 1146 21134544 10.1016/j.surg.2010.09.005
12. F Frasca C Nucera G Pellegriti, et al. 2008 BRAF V600E mutation and biology of papillary thyroid cancer Endocr Relat Cancer 15 191 205 18310287 10.1677/ERC-07-0212 1:CAS:528:DC%2BD1cXkslKnurc%3D (Pubitemid 351449739)
13. DW Ball 2010 Selectively targeting mutant BRAF in thyroid cancer J Clin Endocrinol Metab. 95 1 60 61 20056810 10.1210/jc.2009-2332 1:CAS:528: DC%2BC3cXhtVGhsrk%3D
14. GM Howell SE Carty MJ Armstrong, et al. 2011 Both BRAF V600E mutation and older age (>65 years) are associated with recurrent papillary thyroid cancer Ann Surg Oncol. 18 13 3566 3571 21594703 10.1245/s10434-011-1781-5
15. TH Kim YJ Park JA Lim, et al. 2011 The association of the BRAF V600E mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer. A meta analysis Cancer. 31 343 347
16. JK Nam CK Jung BJ Song, et al. 2011 Is the BRAF V600E mutation useful as a predictor of preoperative risk in papillary thyroid cancer Am J Surg. 29 873 879
17. M Ozturk S Oter 2011 Molecular approach to treatment of hepatocellular carcinoma: new hope for therapeutic targets J Exp Integr Med. 1 2 83 84 10.5455/jeim.130411.ed.004
18. DB Solit LA Garraway CA Pratilas A Sawai G Getz A Basso Q Ye JM Lobo Y She I Osman TR Golub J Sebolt-Leopold WR Sellers N Rosen 2006 BRAF mutation predicts sensitivity to MEK inhibition Nature 439 7074 358 362 16273091 10.1038/nature04304 1:CAS:528:DC%2BD28XkvF2mtw%3D%3D (Pubitemid 43128863)
19. AJ Lanthaler G Spizzo M Mitterer, et al. 2011 Interlaboratory comparison of K-ras testing by real-time PCR and RFLP in colorectal cancer samples Diagn Mol Pathol. 20 2 90 3 21532493 10.1097/PDM.0b013e31820e5f9a
20. MC Zatelli G Trasforini S Leoni, et al. 2009 BRAF V600E mutation analysis increases diagnostic accuracy for papillary thyroid carcinoma in fine-needle aspiration biopsies Eur J Endocrinol. 161 467 473 19574281 10.1530/EJE-09-0353 1:CAS:528:DC%2BD1MXhtFOjtrrF
21. Z Kucukodaci E Akar A Haholu H Baloglu 2011 A valuable adjunct to FNA diagnosis of papillary thyroid carcinoma: in-house PCR assay for BRAF T1799A (V600E) Diagn Cytopathol 39 6 424 427 20607744 10.1002/dc.21406
22. LM Adrienne Y Linwah EC Sally 2010 The utility of BRAF testing in the menagement of papillary thyroid cancer Oncologist. 15 1285 1293 10.1634/theoncologist.2010-0156